UP!
Avalanche Biotechnologies is a publicly traded (NASDAQ:AAVL) biotechnology company in the NASDAQ Biotechnology Index that is worth 245 million that is dedicated to diseases of the eye. This includes macular degeneration, retinal vein occlusion, diabetic macular edema, and others.
| 2016-03-07 | Reiterated Rating | Piper Jaffray | Buy | $15.00 |
| 2016-03-01 | Reiterated Rating | Chardan Capital | Buy | $12.50 to $9.00 |
| 2016-02-18 | Reiterated Rating | Piper Jaffray | Buy | $15.00 |
| 2016-02-02 | Lower Price Target | Jefferies Group | Buy | $20.00 to $12.00 |
| 2016-01-07 | Reiterated Rating | Piper Jaffray | Overweight | $25.00 to $15.00 |
| 2015-08-17 | Upgrade | Chardan Capital | Neutral to Buy | $17.50 |
| 2015-08-14 | Lower Price Target | Jefferies Group | Buy | $51.00 to $20.00 |
| 2015-08-14 | Reiterated Rating | Piper Jaffray | Overweight | $30.00 to $25.00 |
| 2015-08-07 | Lower Price Target | Piper Jaffray | Overweight | $52.00 to $30.00 |
| 2015-07-27 | Reiterated Rating | Chardan Capital | Neutral | $17.50 |
| 2015-06-23 | Upgrade | Chardan Capital | Sell to Neutral | $20.00 |
| 2015-06-17 | Reiterated Rating | Piper Jaffray | Overweight | $52.00 |
| 2015-06-17 | Reiterated Rating | Cowen and Company | Outperform | $55.00 |
| 2015-06-17 | Lower Price Target | SunTrust | Buy to Neutral | $60.00 to $25.00 |
| 2015-06-16 | Downgrade | Chardan Capital | Neutral to Sell | $40.00 to $20.00 |
| 2015-06-16 | Downgrade | SunTrust | Buy to Neutral | $60.00 to $25.00 |
| 2015-06-16 | Reiterated Rating | Jefferies Group | Buy | $51.00 |
| 2015-06-16 | Downgrade | William Blair | Outperform to Market Perform | $53.00 to $24.00 |
| 2015-06-03 | Reiterated Rating | Piper Jaffray | Overweight | $52.00 |
| 2015-05-23 | Reiterated Rating | Jefferies Group | Buy | $51.00 |
| 2015-05-15 | Reiterated Rating | Piper Jaffray | Overweight | $52.00 |
| 2015-03-26 | Boost Price Target | Jefferies Group | Buy | $46.00 to $51.00 |
| 2015-03-26 | Reiterated Rating | Chardan Capital | Hold | $40.00 |
| 2015-03-26 | Boost Price Target | Piper Jaffray | Overweight | $52.00 |
| 2015-03-09 | Initiated Coverage | SunTrust | Buy | $60.00 |
| 2015-03-09 | Reiterated Rating | Piper Jaffray | Overweight | $47.00 |
| 2015-02-19 | Initiated Coverage | Chardan Capital | Neutral | $40.00 |
| 2015-02-13 | Boost Price Target | Jefferies Group | Buy | $40.00 to $46.00 |
| 2014-12-02 | Boost Price Target | Piper Jaffray | $47.00 | |
| 2014-08-25 | Initiated Coverage | William Blair | Outperform | $52.00 |
| 2014-08-25 | Initiated Coverage | Cowen and Company | Outperform | $45.00 |
| 2014-08-25 | Initiated Coverage | Piper Jaffray | Overweight | $39.00 |
| 2014-08-25 | Initiated Coverage | Jefferies Group | Buy | $40.00 |
| 2016-03-07 | Reiterated Rating | Piper Jaffray | Buy | $15.00 |
| 2016-03-01 | Reiterated Rating | Chardan Capital | Buy | $12.50 to $9.00 |
| 2016-02-18 | Reiterated Rating | Piper Jaffray | Buy | $15.00 |
| 2016-02-02 | Lower Price Target | Jefferies Group | Buy | $20.00 to $12.00 |
| 2016-01-07 | Reiterated Rating | Piper Jaffray | Overweight | $25.00 to $15.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In AAVL 2 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| CITY NATIONAL BANK | 10654 |
| SHAPIRO ROBERT N | 104 |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Zygtech, LLC | 10.95% (2438176) | AAVL / |
| Venrock Associates VI, L.P. | 10.63% (2365471) | AAVL / |
| Venrock Healthcare Capital Partners II, L.P. | 10.63% (2365471) | AAVL / |
| REGENERON PHARMACEUTICALS INC | 8.13% (1809098) | AAVL / REGN / |
| Salzman Amber President and COO | 4.01% (891766) | AAVL / |
| Flynn James E Possible Members of 10% Group | 2.82% (627267) | AAVL / ALIM / ASPX / ATRS / AUXL / AXGN / CASM / CYCC / DRNA / EHTH / EMAG / FIXX / HITK / LOXO / NURO / PRTO / REPH / RIGL / STRM / TRGT / TWTI / VNDA / XNPT / |
| Finer Mitchell H. | 2.71% (603069) | AAVL / BLUE / |
| Blumenkranz Mark S. | 2.39% (531322) | AAVL / |
| Schwartz Steven Daniel | 1.79% (398991) | AAVL / |
| Gasmi Mehdi VP, Pharmaceutical Development | 1.30% (289535) | AAVL / |
| Chalberg Thomas W. Chief Executive Officer | 1.16% (258988) | AAVL / |
| PATTERSON LEONE D CFO | 0.81% (180000) | AAVL / TSPT / |
| Barone Samuel B. Chief Medical Officer | 0.77% (172335) | AAVL / |
| Rubio Roman G. SVP, Translational Medicine | 0.74% (165650) | AAVL / |
| Braun Shirley VP, Human Resources | 0.72% (161140) | AAVL / |
| GUERIN JOHN PATRICK ET AL | 0.67% (150000) | AAVL / DJCO / |
| Countouriotis Athena SVP, Chief Medical Officer | 0.67% (150000) | AAVL / AMBI / HALO / TROV / |
| Hull Hans SVP, Legal and Corp. Dev. | 0.62% (137210) | AAVL / |
| Swartzburg Michael Principal Accounting Officer | 0.37% (82113) | AAVL / |
| Spivey Richard N. | 0.32% (70804) | AAVL / |
| Woiwode Thomas | 0.32% (70380) | AAVL / |
| Machado Clarence Patrick | 0.31% (68182) | AAVL / CMRX / ECYT / MDVN / SCYX / TKMR / |
| Carter Eric G | 0.22% (48000) | AAVL / ALDR / |
| Bain Linda Chief Financial Officer | 0.19% (41930) | AAVL / BLUE / |
| Wachter Paul | 0.14% (31951) | AAVL / TWX / VA / |
| Cleveland Paul B President and CEO | 0.10% (22727) | AAVL / AFFY / ALDR / CLDN / SGMO / |
| MCLAUGHLIN JOHN PETER | 0.05% (10333) | AAVL / PDLI / SGEN / |
UM